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SIGNIFICANCE
Psoriasis is associated with cardiometabolic disorders; how-
ever, whether this is due to the common lifestyle-related risk 
factors overweight and smoking is unclear. This study investi-
gated the relationship between psoriasis and cardiometabolic 
disorders taking these confounders into account. The study 
population consisted of women with and without psoriasis 
from a nationwide birth cohort in Denmark. Psoriasis was 
markedly associated with hypercholesterolaemia and hyper-
tension. Women with psoriasis have an increased risk of de-
veloping cardiometabolic disorders in early adult life. Scre-
ening for classic risk factors might therefore be advisable.
Psoriasis is associated with cardiometabolic comorbi-
dity; however, whether this is due to common lifestyle-
related risk factors is unclear. This study investigated 
the association between psoriasis and cardiometabolic 
comorbidity, taking body mass index and smoking into 
account. The population comprised expectant mot-
hers in the Danish National Birth Cohort (established 
1996–2002). During pregnancy, the women were as-
ked about physician-diagnosed psoriasis. Any associa-
tion with self-reported cardiometabolic comorbidity 11 
years later was assessed using logistic regression. The 
cohort was also followed up for hospital-diagnosed co-
morbidity, including cardiac death, until 31 December 
2014, and the risk was assessed using Cox regression. 
A total of 2,435 women with psoriasis (2.90%) and 
81,388 women without were identified. Psoriasis was 
significantly associated with self-reported hypercho-
lesterolaemia (adjusted odds ratio 1.31; 1.01–1.70) 
and hospital-diagnosed hypertension (adjusted hazard 
ratio 1.33; 1.08–1.65). Women with psoriasis have an 
increased risk of developing cardiometabolic comorbi-
dity in early adult life. 
Key words: psoriasis; cardiovascular disease; metabolic di-
sease; comorbidity; risk factor; cardiometabolic disease.
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Psoriasis is an inflammatory skin disease that affects 2–4% of the population in the Western world (1, 
2). Psoriasis is known mainly from registry studies to 
be associated with a range of comorbidities, including 
cardiometabolic diseases (3, 4). The underlying mecha-
nism is unknown, but has been proposed to be a systemic 
inflammatory state known as the “psoriatic march”, in 
which interplay between inflammatory mediators, such 
as cytokines and adipokines, ultimately lead to insulin 
resistance, atherosclerosis, and finally cardiovascular 
diseases, such as myocardial infarction and stroke (5). 
However, this comorbidity could be due to other factors, 
such as overweight and smoking. Data on these important 
confounding factors is seldom available in the registries. 
In this study involving a cohort of women in which there 
was self-reported data available, it was possible to control 
for these confounding factors. The purpose of the present 
study was to investigate the association between psoriasis 
and cardiometabolic comorbidity in women, taking the 
possibly confounding effects of body mass index (BMI) 
and smoking into account (Fig. S11). 
METHODS
The Danish National Birth Cohort (DNBC) was used to identify 
study participants. The DNBC is a nationwide cohort consisting of 
approximately 85,000 unique mothers who were interviewed about 
their health status halfway through pregnancy, between 1996 and 
2002 (6). The mothers and their children have since been followed 
up using interviews and online questionnaires. DNBC data were 
used from the first telephone interview, carried out during the first 
half of pregnancy and the follow-up questionnaire to the mothers 
when the child was 11 years old. In Denmark, all inhabitants are 
assigned a unique 10-digit personal identification number in the 
Danish Civil Registration System (CRS), which allows linkage 
at the individual level with other national registries, including the 
DNBC (7). Data on age and vital status were available from the 
CRS. In addition to the DNBC and the CRS, the Danish National 
Patient Registry (DNPR) was used (8). The DNPR was established 
in 1978 and contains information on all hospital-based inpatient 
diagnoses, and since 1994, also outpatient diagnoses. Diagnosis 
codes are recorded according to the International Classification 
of Diseases, eighth revision (ICD-8) until 1994 and tenth revision 
(ICD-10) thereafter. 
Baseline psoriasis status was obtained from the first interview 
during pregnancy, where the mothers were asked about the pre-
sence of physician-diagnosed psoriasis: “Have you ever had any 
skin disease?” → “Was the skin disease diagnosed by a doctor?” 
→ “What kind of skin disease?” → “Psoriasis?”. In a sub-analysis, 
severe psoriasis was defined as a hospital (inpatient or outpatient) 
diagnosis of psoriasis (ICD-8 696.19 and ICD-10 L40.0, L40.4, 
Psoriasis as a Predictor of Cardiometabolic Comorbidity in Women: 
A Study Based on the Danish National Birth Cohort
Christoffer BLEGVAD1,2, Anne-Marie NYBO ANDERSEN2, Abdulfatah ADAM2, Claus ZACHARIAE1 and Lone SKOV1
1Copenhagen Research Group for Inflammatory Skin (CORGIS), Department of Dermatology and Allergy, Herlev and Gentofte Hospital, 
University of Copenhagen, and 2Section of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
275Psoriasis and cardiometabolic comorbidity in women
Acta Derm Venereol 2019
L40.8, and L40.9) at the time of inclusion in the current study, i.e. 
the first pregnancy interview. This method of using ICD hospital 
diagnoses as the classifier for severe psoriasis has been validated 
previously (3). 
The outcome of interest was cardiometabolic comorbidity. 
Self-reported information on lifetime experience of comorbidity 
was obtained from the 11-year questionnaire in the DNBC. The 
comorbidities were: hypertension, thrombosis (unspecified arterial 
or venous), type 2 diabetes (T2D), and hypercholesterolaemia. 
Furthermore, a composite outcome measure of metabolic syn-
drome was defined in accordance with the International Diabetes 
Federation guidelines: waist circumference ≥80 cm or BMI > 30 
kg, plus 2 of the following: T2D, hypertension, or dyslipidaemia 
(9). Waist circumference and BMI were also obtained from the 
11-year questionnaire in this case. For the hospital diagnoses, 
data from the DNPR were used. The ICD-10 diagnoses included 
were: hypertension (I10–I15), ischaemic heart disease (I20–I25, 
including cardiac death), T2D (E11), and hypercholesterolaemia 
(E78.0).
Information on the possible confounding factors pre-pregnancy 
BMI and smoking were obtained from the first pregnancy inter-
view in the DNBC. The mother’s age at this time-point was also 
used for adjustment.
Statistical analysis
Baseline characteristics were expressed with means and standard 
deviations for continuous variables, and used frequencies and 
percentages in the case of categorical variables. Statistical testing 
for differences was performed using unpaired Student’s t-test and 
χ2 test, respectively. Two separate sub-studies were performed. 
Firstly, multiple logistic regression was used to estimate crude and 
adjusted odds ratios (ORs) for the association between baseline 
psoriasis and self-reported cardiometabolic comorbidity, as stated 
by subjects who responded to the 11-year questionnaire. Secondly, 
Cox regression was used to estimate crude and adjusted hazard 
ratios (HRs) to estimate the risk of incident hospital-diagnosed 
cardiometabolic comorbidity in all women with and without base-
line psoriasis. Here, the women were followed up from the date of 
the first pregnancy interview to the date of cardiometabolic event, 
death, or 31 December 2014, whichever came first. Women with a 
history of event before the time of inclusion were excluded from 
the analysis. Calendar time was the underlying time variable. Both 
sub-studies were adjusted for age, pre-pregnancy BMI, and smo-
king status from the first pregnancy interview. To investigate the 
small individual effect of each confounding factor, sub-analyses 
adjustment was carried out for 1 confounder at a time. All results 
are reported with 95% confidence intervals (CIs) where possible. 
Analyses were performed using SAS statistical software version 
9.4 (SAS Institute Inc., Cary, NC, USA) and STATA software 
version 14.0 (StataCorp, College Station, TX, USA).
The study was performed in accordance with the “Strengthe-
ning the Reporting of Observational Studies in Epidemiology 
(STROBE)” statement (10). Approval was granted as required 
from the Danish Data Protection Agency (reference Sund-2017-
09), while ethical approval is not required for registry-based health 
studies in Denmark.
RESULTS
A total of 83,823 women who had participated in the 
first interview during pregnancy were identified, 2,435 
(2.90%) of whom had reported having psoriasis (Table 
I and Fig. S21). At the time of inclusion, women with 
psoriasis were slightly older, on average, than women 
without psoriasis, they generally had a higher BMI, and 
a higher proportion smoked (38.1% vs. 26.4%). Of all 
the women, 125 (0.15%) had severe (hospital-diagnosed) 
psoriasis at the time of inclusion. The 11-year follow-
up questionnaire was completed by 38,903 women 
(46.41%), 1,047 (2.69%) of whom had psoriasis and 
52 (0.13%) of whom had severe psoriasis at inclusion.
In the first sub-study of baseline psoriasis and self-
reported comorbidity from the 11-year follow-up 
questionnaire (Table II), it was found that hypercholes-
terolaemia was significantly associated with psoriasis 
even after adjusting for confounders (adjusted OR 1.31; 
1.01–1.70). The other self-reported comorbidities of 
interest (hypertension, thrombosis, T2D, and metabolic 
syndrome) did not show any significant associations 
with psoriasis.
A sub-analysis of the hypercholesterolaemia results 
examined the (small) confounding effects of age, BMI, 
and smoking status separately, and they were found to be 
roughly equally important when looking at the respective 
adjusted ORs (data not shown).
When looking at severe (i.e. hospital-diagnosed) base-
line psoriasis, a strong association with hypercholestero-
laemia was found (adjusted OR 2.71; 1.41–6.41) (Table 
III). Interestingly, the composite outcome of metabolic 
Table I. Characteristics at the time of inclusion during pregnancy
Women with 
no psoriasis
(n = 81,388)
Women with 
psoriasis
(n = 2,435) p-value
Age, years, mean (SD) 29.9 (4.3) 30.4 (4.5) < 0.0001
Body mass index, kg/m2, mean (SD) 23.6 (4.3) 24.1 (4.6) < 0.0001
Smokers, n (%) 21,510 (26.4) 927 (38.1) < 0.0001
SD: standard deviation.
Table II. Association between baseline psoriasis and self-reported cardiometabolic comorbidity from the 11-year follow-up questionnaire
Women with no psoriasis
n (%)
Women with psoriasis
n (%) Crude OR (95% CI) Adjusted OR* (95% CI)
Hypertension 3,162 (8.35) 90 (8.60) 1.03 (0.83–1.29) 0.95 (0.76–1.19)
Thrombosis 522 (1.38) 13 (1.24) 0.90 (0.52–1.56) 0.85 (0.49–1.48)
Type 2 diabetes
  BMI < 25 kg 113 (0.40) 2 (0.28) 0.69 (0.17–2.78) 0.60 (0.15–2.44)
  BMI ≥ 25 kg 220 (2.41) 8 (2.63) 1.10 (0.54–2.24) 0.94 (0.45–1.94)
Hypercholesterolaemia 1,635 (4.32) 65 (6.21) 1.47 (1.14–1.89) 1.31 (1.01–1.70)
Metabolic syndromea 471 (1.24) 15 (1.43) 1.15 (0.69–1.94) 0.93 (0.55–1.58)
aDefined as waist circumference ≥ 80 cm or body mass index (BMI) >30 kg from the 11-year questionnaire, plus 2 of any of the following: type 2 diabetes, hypertension, 
hypercholesterolaemia. 
*Adjusted for age, body mass index, and smoking. OR: odds ratio; CI: confidence interval.
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syndrome showed a very strong association with severe 
psoriasis (adjusted OR 4.63; 1.38–15.47), even though 
no such association was found in the analysis of self-re-
ported psoriasis. Again, no significant associations were 
found between severe psoriasis and the self-reported 
diagnoses of hypertension, thrombosis, or T2D.
In the second sub-study of baseline psoriasis and 
incident hospital-diagnosed comorbidity, an increased 
risk was found in the crude analyses of all diagnoses 
included: hypertension, ischaemic heart disease, T2D, 
and hypercholesterolaemia (Table IV). In the case of 
T2D, there was a highly significant interaction between 
psoriasis and BMI. We therefore stratified according to 
normal weight (BMI < 25 kg) or overweight (BMI ≥ 25 
kg) in all analyses of T2D, and the increased risk of T2D 
was then evident only in the overweight women with 
psoriasis. In the fully adjusted model, only hypertension 
remained at significantly increased risk (adjusted HR 
1.33; 1.08–1.65).
Again, the isolated effect of the separate confounders 
for hypertension were examined and it was found that 
age was the most important, followed by smoking sta-
tus. Adjustment for BMI alone did not affect the crude 
estimate (data not shown).
In a sub-analysis of severe baseline psoriasis, the 
increased risk of hospital-diagnosed hypertension was 
even more evident (adjusted HR 2.14; 1.02–4.49). An 
increased risk of T2D was also found in the overweight 
women with psoriasis (adjusted HR 4.50; 1.12–18.07) but 
this was based on very few cases. The absolute number of 
cases in the remaining categories was less than 3, and for 
reasons of confidentiality, the results cannot be shown.
DISCUSSION
In this study, of mainly younger women with psoriasis, an 
increased risk of early cardiometabolic comorbidity was 
found. After adjustment for the important confounders 
age, BMI, and smoking status, it was found that the risk 
of self-reported hypercholesterolaemia and hospital-
diagnosed hypertension was significantly increased in 
women with psoriasis. Overall, these data support the 
idea that psoriasis is an important independent risk fac-
tor for cardiometabolic disease. The present study also 
shows the importance of taking the confounding effect 
of BMI and smoking into account.
In general, the results showed a unidirectional asso-
ciation between psoriasis and the comorbidities investi-
gated. This supports the results of previous research on 
psoriasis and hypertension (11), ischaemic heart disease 
(3, 12), T2D (11, 13, 14), and hypercholesterolaemia (15, 
16). Our results are also consistent with the hypothesis 
of there being an underlying common pathogenetic me-
chanism, such as the “psoriatic march”, as described in 
the Introduction (5).
Only self-reported hypercholesterolaemia and 
hospital-diagnosed hypertension were at significantly 
increased risk in the fully adjusted model, but the women 
in our study were young in relation to development of 
the comorbidities under investigation, and there was 
still a general tendency of increased risk. As shown by 
Gelfand et al., the increased risk of myocardial infarc-
tion in psoriasis is most obvious in younger patients with 
severe psoriasis (12). Our study supports the notion that 
psoriasis in younger patients carries an independent risk 
of cardiovascular risk factors and comorbidity, and that 
Table III. Association between severe baseline psoriasis and self-reported cardiometabolic comorbidity from the 11-year follow-up 
questionnaire
Women with no psoriasis
n (%)
Women with psoriasis
n (%) Crude OR (95% CI) Adjusted OR* (95% CI)
Hypertension 3,247 (8.36) 5 (9.62) 1.17 (0.46–2.94) 1.12 (0.44–2.87)
Thrombosis 533 (1.37) < 3 2.88 (0.70–11.85) 1.34 (0.19–9.75)
Type 2 diabetes
  BMI < 25 kg 115 (0.40) 0 (0.00) – –
  BMI ≥ 25 kg 228 (2.42) 0 (0.00) – –
Hypercholesterolaemia 1,694 (4.36) 6 (11.54) 2.86 (1.22–6.71) 2.71 (1.41–6.41)
Metabolic syndromea 483 (1.24) 3 (5.77) 4.87 (1.51–15.66) 4.63 (1.38–15.47)
aDefined as waist circumference ≥80 cm or body mass index (BMI) >30 kg from the 11-year questionnaire, plus 2 of any of the following: type 2 diabetes, hypertension, 
hypercholesterolaemia. *Adjusted for age, BMI, and smoking.
OR: odds ratio; CI: confidence interval.
Table IV. Risk of incident hospital-diagnosed cardiometabolic comorbidity in women with baseline psoriasis
Women with no psoriasis 
n
Women with psoriasis 
n Crude HR (95% CI) Adjusted HR* (95% CI)
Hypertension 2,173 91 1.41 (1.14–1.74) 1.33 (1.08–1.65)
Ischaemic heart disease 747 34 1.53 (1.08–2.15) 1.32 (0.93–1.86)
Type 2 diabetes
  BMI < 25 kg 138   4 1.03 (0.38–2.78) 0.89 (0.33–2.41)
  BMI ≥ 25 kg 312 18 1.64 (1.02–2.64) 1.51 (0.94–2.43)
Hypercholesterolaemia 446 21 1.58 (1.02–2.44) 1.36 (0.88–2.12)
*Adjusted for age, body mass index (BMI), and smoking.
HR: hazard ratio; CI: confidence interval.
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this might be even stronger in patients with severe pso-
riasis. In the case of self-reported metabolic syndrome, 
an extremely strong association was found, but it was 
based on only 3 cases, and could simply have been due 
to chance.
A highly significant interaction was found between 
psoriasis and BMI in relation to T2D, and we therefore 
performed the analyses with stratification according to 
BMI. Interestingly, it was only in overweight women that 
psoriasis was an independent risk factor for T2D, and to 
our knowledge this has not been found previously (17).
In the analysis of psoriasis in relation to self-reported 
comorbidity (Table II), there was a clear association 
between hypercholesterolaemia and psoriasis, which re-
mained significant after adjustment for confounding fac-
tors. However, this was not as obvious in the analysis of 
hospital-diagnosed comorbidity (Table IV), even though 
the result was still in agreement with the result of analysis 
of the self-reported data. One reason for this could be 
that hypercholesterolaemia is most often treated by the 
general practitioner, and there is therefore no information 
available in the hospital-based registries. One way of 
circumventing this issue would be to use claimed medical 
prescriptions for certain drugs as a proxy for disease. 
This method is, however, not viable for a diagnosis such 
as hypercholesterolaemia. Although it is a disease that 
must be measured and diagnosed by a physician, many 
patients try dietary intervention or have no treatment at 
all, and the disease is therefore never recorded.
In contrast, a markedly increased risk of hypertension 
was found in the analysis of hospital-diagnosed comor-
bidity (Table IV) that was not identified in the analysis 
of self-reported data. One explanation for this could be 
that hypertension can be diagnosed at home and there-
fore might be over-reported in the self-reported data. 
Furthermore, the analysis of self-reported comorbidity 
had less power than the analysis of hospital-diagnosed 
comorbidity, since its study population was less than half 
the size. It is therefore possible that the risk contribution 
of psoriasis was attenuated, making it difficult to show 
any associations between psoriasis and hypertension 
in the smaller amount of self-reported data. A “healthy 
worker effect” among those who responded to the 11-
year follow-up may also have reduced the prevalence 
of comorbidity in the self-reported data. This would not 
be a problem in the hospital data, since hypertension is 
diagnosed by trained professionals and the full baseline 
population is used. Here, however, there is a risk of 
surveillance bias due to patients with psoriasis possibly 
having more doctor’s visits and therefore being more 
likely to get a diagnosis of hypertension, so this should be 
kept in mind. We tried to address discrepancies in what is 
recorded by analysing both self-reported comorbidity and 
hospital-diagnosed comorbidity in the same population. 
Women with psoriasis were identified on both a self-re-
ported physician-diagnosed basis and a registry/hospital-
diagnosed basis. The validity of the self-reported measure 
in the current study is high. As part of a clinical study, we 
have previously validated this self-reported physician-
diagnosed psoriasis and could confirm the diagnosis in a 
satisfactory 80.8% of cases (18). Furthermore, in women 
with severe (hospital-diagnosed) psoriasis at inclusion 
time, 83.2% also reported having psoriasis in the DNBC. 
This validation of the psoriasis diagnosis is a strength 
of the current study compared with previous research 
(11). Self-reported data on the important confounders 
BMI and smoking were available, information that is 
not often available in the large registries. It was also 
possible to analyse both self-reported comorbidity and 
hospital-diagnosed comorbidity. It is known that some 
selection bias exists in the DNBC, and the participants 
are slightly healthier and have higher socioeconomic 
status than the source population; however, a study on 
the effect of non-participation showed no resulting bias 
for 3 different associations (19, 20). The better health and 
socioeconomic status, of course, affects women with and 
without psoriasis equally, but it can be speculated that it 
is more difficult to show significant associations with the 
comorbidities examined because there are fewer events 
overall in our cohort. In combination with the fact that 
the women are relatively young and therefore have not 
reached an age at which cardiometabolic diseases become 
prevalent, our results can be considered to be very con-
servative and may just be the “tip of the iceberg”. Our 
analyses of severe psoriasis were unfortunately limited 
by the low number of cases, but an even greater risk 
was clear in self-reported hypercholesterolaemia and 
hospital-diagnosed hypertension. The remaining results 
in the analysis of severe psoriasis have been presented 
with broad confidence intervals and should be interpre-
ted accordingly. Regarding generalizability, our study 
was carried out in a female cohort and the results might 
therefore not be directly extrapolatable to the general 
population.
In conclusion, the present study shows that early 
screening for the classic cardiometabolic risk factors 
hypertension, hypercholesterolaemia, and hyperglycae-
mia may be of importance when treating patients with 
psoriasis, and that this also applies to younger patients. 
Furthermore, weight loss with regard to prevention of 
T2D appears to be even more crucial for patients with 
psoriasis. Our results support the underlying hypothesis 
of the “psoriatic march”.
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